Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&… อ่านเพิ่ม